Oral administration of bovine lactoferrin reduces trinitrobenzene sulphonic acid-induced colitis in rats by modulation of the immune system and correction of cytokine imbalance

2001 ◽  
Vol 120 (5) ◽  
pp. A687-A687
Author(s):  
J TOGAWA ◽  
K TANAKA ◽  
M INAMORI ◽  
T UMEZAWA ◽  
A NAKAJIMA ◽  
...  
2002 ◽  
Vol 17 (12) ◽  
pp. 1291-1298 ◽  
Author(s):  
JUN-ICHI TOGAWA ◽  
HAJIME NAGASE ◽  
KATSUAKI TANAKA ◽  
MASAHIKO INAMORI ◽  
ATSUSHI NAKAJIMA ◽  
...  

2002 ◽  
Vol 283 (1) ◽  
pp. G187-G195 ◽  
Author(s):  
Jun-Ichi Togawa ◽  
Hajime Nagase ◽  
Katsuaki Tanaka ◽  
Masahiko Inamori ◽  
Tadashi Umezawa ◽  
...  

Natural immunomodulator lactoferrin is known to exert an anti-inflammatory effect. However, there have been no studies that examine the mode of action of lactoferrin in reducing intestinal damage. We investigated the effect of lactoferrin on a trinitrobenzenesulfonic acid (TNBS)-induced colitis model in rats. Bovine lactoferrin was given once daily through gavage, starting 3 days before (preventive mode) or just after TNBS administration (treatment mode) until death. The distal colon was removed to be examined. Colitis was attenuated by lactoferrin via both modes in a dose-dependent manner, as reflected by improvement in macroscopic and histological scores and myeloperoxidase activity. Lactoferrin caused significant induction of the anti-inflammatory cytokines interleukin (IL)-4 and IL-10, significant reductions in the proinflammatory cytokines tumor necrosis factor-α and IL-1β, and downregulation of the nuclear factor-κB pathway. We concluded that lactoferrin exerts a protective effect against colitis in rats via modulation of the immune system and correction of cytokine imbalance. Lactoferrin has potential as a new therapeutic agent for inflammatory bowel disease.


2004 ◽  
Vol 39 (12) ◽  
pp. 1250-1258 ◽  
Author(s):  
F. Lamine ◽  
H. Eutamène ◽  
J. Fioramonti ◽  
L. Buéno ◽  
V. Théodorou

2003 ◽  
Vol 124 (4) ◽  
pp. A496
Author(s):  
Isao Tsune ◽  
Kenich Ikejima ◽  
Miyoko Hirose ◽  
Mutsuko Yoshikawa ◽  
Nobuyuki Enomoto ◽  
...  

2006 ◽  
Vol 84 (3) ◽  
pp. 377-380 ◽  
Author(s):  
Rosalba Paesano ◽  
Francesco Torcia ◽  
Francesca Berlutti ◽  
Enrica Pacifici ◽  
Valeria Ebano ◽  
...  

Iron deficiency anemia (IDA) during pregnancy continues to be of world-wide concern. IDA is a risk factor for preterm delivery and subsequent low birth weight, and possibly for poor neonatal health. Iron supplementation in pregnancy is a widely recommended practice, yet intervention programs have met with many controversies. In our study, 300 women at different trimesters of pregnancy were enrolled in a trial of oral administration of ferrous sulfate (520 mg once a day) or 30% iron-saturated bovine lactoferrin (bLf) (100 mg twice a day). Pregnant women refusing treatment represented the control group. In this group hemoglobin and total serum iron values measured after 30 d without treatment decreased significantly, especially in women at 18–31 weeks of pregnancy. In contrast, after 30 d of oral administration of bLf, hemoglobin and total serum iron values increased and to a greater extent than those observed in women treated orally for 30 d with ferrous sulfate, independently of the trimester of pregnancy. Unlike ferrous sulfate, bLf did not result in any side effects. These findings lead us to hypothesize that lactoferrin could influence iron homeostasis directly or through other proteins involved in iron transport out of the intestinal cells into the blood.


Sign in / Sign up

Export Citation Format

Share Document